Units of ContraFect Corp., a biotechnology company based in Yonkers, on Tuesday began trading on the Nasdaq Capital Market, an exchange for corporations with small market capitalizations.
The company priced the units, of which 6 million will be offered, at $6 each, generating $36 million in gross proceeds from the initial public offering. On or prior to Sept. 12, the units will separate into three classes of securities. The common stock is expected to trade on the Nasdaq Capital Market under the symbol CFRX, Class A warrants will trade under the ticker symbol CFRXW and Class B warrants will trade under the symbol CFRXZ.
Maxim Group L.L.C. is the sole book runner for the offering and has a 45-day option to purchase an additional 900,000 units from ContraFect to cover over-allotments. Roth Capital Partners L.L.C. has acted as financial adviser to ContraFect in connection with the offering.
In an email sent to the Business Journal, ContraFect CEO Julia P. Gregory said the company would use the proceeds of the offering to further its work developing treatments for Staph bloodstream infections and influenza, as well as research and general corporate purposes.
